Search Results - "Squires, M.S."

512 NCIC CTG IND.181: Phase I study of AT9283 given as a weekly 24 hour infusion by Gelmon, K, Dent, S, Chi, K, Jonker, D, Wainman, N, Simpson, R, Capier, K, Chen, E, Squires, M.S, Seymour, L

Get full text

491 NCIC CTG IND.177: Phase I study of AT7519M given as a short infusion twice weekly by Hotte, S.J, Chen, E.X, McIntosh, L, Hirte, H.W, Turner, S, Jarvi, A, Squires, M.S, Seymour, L

Get full text

A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors by Mahadevan, D., Plummer, R., Squires, M.S., Rensvold, D., Kurtin, S., Pretzinger, C., Dragovich, T., Adams, J., Lock, V., Smith, D.M., Von Hoff, D., Calvert, H.

“…AT7519 is an inhibitor of multiple cyclin-dependent kinases (CDKs). Based on potent antitumor activity in preclinical models, a first-in-human clinical trial…”
Get full text

117 Identification of novel cyclin dependent kinase 1/2 inhibitors using fragment based high-throughput X-ray crystallography and structure based drug design by Wyatt, P.G., Berdini, V., Carr, M.G., Curry, J.E., Davis, D.J., O'Reilly, M., Saxty, G., Squires, M.S., Woodhead, A.J., Woolford, A.J.-A.

Get full text